Stock ACAD ACADIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
16.71 USD +2.45% Intraday chart for ACADIA Pharmaceuticals Inc. -0.65% -46.63%
Apr. 23 Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada MT
Apr. 22 Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,589 8,499 3,752 2,578 5,140 2,753 - -
Enterprise Value (EV) 1 5,892 7,867 3,231 2,161 4,702 2,147 1,890 1,448
P/E ratio -26.7 x -29.9 x -22.2 x -11.9 x -84.6 x 26.6 x 12.8 x 9.18 x
Yield - - - - - - - -
Capitalization / Revenue 19.4 x 19.2 x 7.75 x 4.98 x 7.08 x 2.85 x 2.53 x 2.22 x
EV / Revenue 17.4 x 17.8 x 6.67 x 4.18 x 6.47 x 2.22 x 1.74 x 1.17 x
EV / EBITDA -24.2 x -27.7 x -19.3 x -9.75 x -69.3 x 20.6 x 8.37 x 3.72 x
EV / FCF -38.7 x -54.7 x -25.5 x -19 x 282 x 20.4 x 7.75 x 3.86 x
FCF Yield -2.58% -1.83% -3.92% -5.28% 0.35% 4.91% 12.9% 25.9%
Price to Book 9.5 x 13.6 x 6.95 x 6.44 x 11.9 x 4.54 x 3.01 x 2.12 x
Nbr of stocks (in thousands) 154,025 158,978 160,756 161,931 164,180 164,772 - -
Reference price 2 42.78 53.46 23.34 15.92 31.31 16.71 16.71 16.71
Announcement Date 2/26/20 2/24/21 2/28/22 2/27/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 339.1 441.8 484.1 517.2 726.4 967.2 1,089 1,238
EBITDA 1 -243.8 -283.7 -167.1 -221.6 -67.83 104.2 225.8 389.7
EBIT 1 -246.5 -286.6 -170.4 -223.6 -73.38 106.6 215.4 334
Operating Margin -72.71% -64.87% -35.2% -43.23% -10.1% 11.02% 19.78% 26.97%
Earnings before Tax (EBT) 1 -234.4 -281 -167.5 -213.4 -51.04 109.1 232.3 347.1
Net income 1 -235.3 -281.6 -167.9 -216 -61.29 109.6 220.9 321.5
Net margin -69.38% -63.74% -34.67% -41.76% -8.44% 11.33% 20.29% 25.96%
EPS 2 -1.600 -1.790 -1.050 -1.340 -0.3700 0.6288 1.302 1.819
Free Cash Flow 1 -152.3 -143.8 -126.8 -114 16.65 105.4 244 374.7
FCF margin -44.9% -32.54% -26.19% -22.05% 2.29% 10.9% 22.41% 30.26%
FCF Conversion (EBITDA) - - - - - 101.16% 108.05% 96.15%
FCF Conversion (Net income) - - - - - 96.2% 110.46% 116.54%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/26/20 2/24/21 2/28/22 2/27/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 131.6 130.8 115.5 134.6 130.7 136.5 118.5 165.2 211.7 231 208.7 242 254.3 261.7 221.1
EBITDA 1 -13.73 -44.12 -112.1 -33.04 -30.36 -45.57 -53.16 4.803 -56.05 36.58 10.08 34.59 42.04 22.49 -
EBIT 1 -15.3 -44.66 -113 -33.65 -30.87 -46.06 -53.58 3.037 -57.78 34.94 6.291 33.11 38.23 30.98 59.7
Operating Margin -11.63% -34.15% -97.88% -25.01% -23.61% -33.75% -45.23% 1.84% -27.29% 15.12% 3.01% 13.68% 15.03% 11.84% 27%
Earnings before Tax (EBT) 1 -14.79 -42.9 -112.6 -33.57 -26.42 -40.89 -44.94 6.343 -52.14 39.7 9.107 35.79 35.79 27.49 59.7
Net income 1 -14.46 -43.09 -113.1 -34.01 -27.18 -41.72 -43.02 1.114 -65.18 45.8 8.071 34.4 34.72 27.73 47.2
Net margin -10.98% -32.96% -97.91% -25.28% -20.8% -30.57% -36.32% 0.67% -30.79% 19.82% 3.87% 14.22% 13.65% 10.59% 21.35%
EPS 2 -0.0900 -0.2700 -0.7000 -0.2100 -0.1700 -0.2600 -0.2700 0.0100 -0.4000 0.2800 0.0552 0.1918 0.1994 0.1702 0.2800
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/8/21 2/28/22 5/4/22 8/8/22 11/2/22 2/27/23 5/8/23 8/2/23 11/2/23 2/27/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 697 632 521 417 439 606 864 1,305
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -152 -144 -127 -114 16.7 105 244 375
ROE (net income / shareholders' equity) -39.9% -42.5% -28.7% -45.9% -14.7% 22% 28.7% 27.8%
ROA (Net income/ Total Assets) -35.6% -36% -22.6% -33.5% -9.17% 16.4% 25.9% 15.6%
Assets 1 661.7 782.9 741.4 644 668.4 668.9 853.1 2,060
Book Value Per Share 2 4.500 3.930 3.360 2.470 2.640 3.680 5.550 7.880
Cash Flow per Share 2 -1.030 -0.8700 -0.7800 -0.7100 0.1000 1.070 1.310 3.560
Capex 1 1.13 7.59 1.12 - 0.05 3.14 2.78 2.03
Capex / Sales 0.33% 1.72% 0.23% - 0.01% 0.32% 0.25% 0.16%
Announcement Date 2/26/20 2/24/21 2/28/22 2/27/23 2/27/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ACADIA Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.71 USD
Average target price
29.09 USD
Spread / Average Target
+74.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ACADIA PHARMACEUTICALS INC. Stock ACADIA Pharmaceuticals Inc.
-46.63% 2.75B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACAD Stock
  4. Financials ACADIA Pharmaceuticals Inc.